Comparative Analysis of Surgical Outcomes Between Robotic-Assisted Pyelolithotomy and Mini-Percutaneous Nephrolithotomy for Renal Stones Larger Than 2 cm in Older Adults: A One-Year Follow-Up Study.
{"title":"Comparative Analysis of Surgical Outcomes Between Robotic-Assisted Pyelolithotomy and Mini-Percutaneous Nephrolithotomy for Renal Stones Larger Than 2 cm in Older Adults: A One-Year Follow-Up Study.","authors":"Hong-An Tu, Shu-Chuan Weng, Yu-Hsiang Lin, Chien-Lun Chen, Yu-Ting Chen, Horng-Heng Juang, Chen-Pang Hou","doi":"10.2147/IJNRD.S532866","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to compare the surgical outcomes of robotic-assisted pyelolithotomy (RAPL) and mini-percutaneous nephrolithotomy (mini-PCNL) specifically in older adults with renal stones more than 2cm. We hypothesized that robotic-assisted pyelolithotomy (RAPL) is a safe and effective approach for managing large renal stones (>2 cm) in older adults.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 605 patients aged 50-80 years who underwent either RAPL (n=31) or mini-PCNL (n=574) for renal stones >2 cm at Chang Gung Memorial Hospital, Taiwan, between December 2016 and November 2023. Patients were selected based on predefined inclusion and exclusion criteria. Key outcomes measured included stone-free rate, complication rate, hospital stay duration, and re-intervention rates. All patients were followed for at least one year postoperatively.</p><p><strong>Results: </strong>RAPL patients exhibited a longer total operative time (165.2 vs 127.4 minutes, p = 0.016) but experienced significantly shorter hospital stays (1.8 vs 4.0 days, p < 0.001), lower complication rates (6.5% vs 27.7%, p < 0.05), and higher SFRs (90.3% vs 60.8%, p < 0.001). Blood transfusion, postoperative discomfort, and re-intervention rates were also markedly lower in the RAPL group.</p><p><strong>Conclusion: </strong>For older patients with large renal stones, RAPL is a promising alternative to mini-PCNL, offering better stone clearance, fewer complications, and quicker recovery. Its minimally invasive, tissue-sparing approach benefits those at higher postoperative risk.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"177-185"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182092/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nephrology and Renovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IJNRD.S532866","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This study aimed to compare the surgical outcomes of robotic-assisted pyelolithotomy (RAPL) and mini-percutaneous nephrolithotomy (mini-PCNL) specifically in older adults with renal stones more than 2cm. We hypothesized that robotic-assisted pyelolithotomy (RAPL) is a safe and effective approach for managing large renal stones (>2 cm) in older adults.
Patients and methods: We retrospectively analyzed 605 patients aged 50-80 years who underwent either RAPL (n=31) or mini-PCNL (n=574) for renal stones >2 cm at Chang Gung Memorial Hospital, Taiwan, between December 2016 and November 2023. Patients were selected based on predefined inclusion and exclusion criteria. Key outcomes measured included stone-free rate, complication rate, hospital stay duration, and re-intervention rates. All patients were followed for at least one year postoperatively.
Results: RAPL patients exhibited a longer total operative time (165.2 vs 127.4 minutes, p = 0.016) but experienced significantly shorter hospital stays (1.8 vs 4.0 days, p < 0.001), lower complication rates (6.5% vs 27.7%, p < 0.05), and higher SFRs (90.3% vs 60.8%, p < 0.001). Blood transfusion, postoperative discomfort, and re-intervention rates were also markedly lower in the RAPL group.
Conclusion: For older patients with large renal stones, RAPL is a promising alternative to mini-PCNL, offering better stone clearance, fewer complications, and quicker recovery. Its minimally invasive, tissue-sparing approach benefits those at higher postoperative risk.
目的:本研究旨在比较机器人辅助肾盂取石术(RAPL)和微型经皮肾取石术(mini-PCNL)在肾结石超过2cm的老年人中的手术效果。我们假设机器人辅助肾盂取石术(RAPL)是一种安全有效的治疗老年人大肾结石(bbb20厘米)的方法。患者和方法:我们回顾性分析了2016年12月至2023年11月台湾长工纪念医院605例年龄50-80岁的肾结石患者,这些患者接受了RAPL (n=31)或mini-PCNL (n=574)。根据预先确定的纳入和排除标准选择患者。测量的主要结果包括无结石率、并发症率、住院时间和再干预率。所有患者术后随访至少1年。结果:RAPL患者总手术时间较长(165.2 vs 127.4 min, p = 0.016),住院时间较短(1.8 vs 4.0 d, p < 0.001),并发症发生率较低(6.5% vs 27.7%, p < 0.05), SFRs较高(90.3% vs 60.8%, p < 0.001)。RAPL组的输血、术后不适和再干预率也明显降低。结论:对于年龄较大的肾结石患者,RAPL是一种有希望的替代mini-PCNL的方法,可以提供更好的结石清除,更少的并发症,更快的恢复。其微创、组织保留入路有利于术后风险较高的患者。
期刊介绍:
International Journal of Nephrology and Renovascular Disease is an international, peer-reviewed, open-access journal focusing on the pathophysiology of the kidney and vascular supply. Epidemiology, screening, diagnosis, and treatment interventions are covered as well as basic science, biochemical and immunological studies. In particular, emphasis will be given to: -Chronic kidney disease- Complications of renovascular disease- Imaging techniques- Renal hypertension- Renal cancer- Treatment including pharmacological and transplantation- Dialysis and treatment of complications of dialysis and renal disease- Quality of Life- Patient satisfaction and preference- Health economic evaluations. The journal welcomes submitted papers covering original research, basic science, clinical studies, reviews & evaluations, guidelines, expert opinion and commentary, case reports and extended reports. The main focus of the journal will be to publish research and clinical results in humans but preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies and interventions.